ARTICLE | Translation in Brief
Cold Spring Harbor team finds off-target activity can drive antitumor effects
A discovery that 10 drug candidates don't act through their reported target to kill cancer cells suggests companies revise how they validate targets.
September 11, 2019 8:47 PM UTC
Drug developers may need to revise how they validate drug targets, according to a Cold Spring Harbor Laboratory study that found 10 clinical oncology candidates killed tumor cells by hitting unintended targets.
The study also revealed a new target that could be inhibited to treat cancer...